We began developing Melaseq, the worlds first non-invasive cancer biomarker in 2016, after years of research in cancer genomics and assay development.
Click to view an annotated timeline of our Melaseq development progress and company milestones.
Geneseq Biosciences founded
Company launched in Melbourne, Australia to translate the latest developments in cancer biomarker research into clinically useful diagnostic and prognostic tests.
Melanoma Genomic database created
Blood samples from melanoma patients procured from international clinical research biobanks Cureline Inc and Folio Biosciences. Nanostring ‘whole-microRNAome’ analysis performed on each specimen to create a clinically-annotated database of circulating biomarker candidates.
Melaseq algorithm developed
Geneseq melanoma database mined to identify the optimal set of diagnostic circulating microRNAs in patient blood (n=38).
Accepted to Melbourne Health Accelerator Spring 2017 Cohort
Geneseq Biosciences invited to participate in Australia’s first hospital ‘in-situ’ accelerator program, in association with Health Round Table. The MHx program provides innovative start-up companies with the opportunity to access the world-class Royal Melbourne Hospital health system and empowers clinicians and researchers to pursue an entrepreneurial mindset within a structured collaborative framework.
Melaseq patent application submitted
Patent “A method of diagnosis and staging of melanoma using microRNA gene expression” submitted to Australian Patent Office (application 2017903978) covering AU/EU/US regions.
Patient recruitment commenced for validation study 2
Melaseq analysis of patient blood samples (i) before and (ii) 2-4 weeks after melanoma surgery, to study the impact of treatment on the multi-gene score.
World Melanoma Congress 2017 Presentation
Melaseq development and validation results presented at the premier joint congress on melanoma that brings together the world’s leading melanoma researchers and clinicians to showcase the latest developments in melanoma diagnosis, treatment and research.
Graduation from Melbourne Health Accelerator (MHx)
Completed the Melbourne Health Incubator program and pitched to several hundred colleagues, partners and potential investors at the final session.
Melaseq published in the British Journal of Cancer
Melaseq is one step closer to being available for use in Australia after being published in of the world’s most respected medical journals, The British Journal of Cancer.
Second Melaseq clinical study to be published in Melanoma Research
The world’s first blood test for Melanoma, developed by Geneseq Biosciences (Melbourne, Australia), has been further validated by a new clinical study to be published in the journal ‘Melanoma Research’
Partnership with Australian Clinical Labs
Geneseq Biosciences and Australian Clinical Labs today announced they will partner to bring the first non-invasive melanoma test to market under the trademark Melaseq™. Clinical Labs is the largest pathology provider to public hospitals in Australia, with over 90 NATA accredited laboratories and 900 collection sites nation-wide.
Melaseq Analytical Validation Studies Commenced
Laboratory work commenced at Australian Clinical Labs Clayton (VIC) headquarters, generating Melaseq accuracy and reproducibility data.
Third Melaseq validation study published in PLOS ONE
New research published in PLOS ONE, shows that the Melaseq™ test can (i) be performed using FFPE skin biopsy tissue, (ii) predict a patient’s length of survival independent to staging and (iii) measures gene activity involved in the regulation of important melanoma immunotherapy targets.
Melaseq Prospective Validation Study Approved
Permission to commence an extended technical and clinical validation of Melaseq, using prospectively-collected patient specimens. Multiple study sites enrolled and patient recruitment commenced.
Patient Recruitment Commenced
Patient recruitment and specimen collection commenced at multiple leading skin cancer clinics around Australia.
Melaseq-FFPE Validation Study Published
Multiple international studies have described the challenge of providing accurate and reproducible histopathological assessments of melanocytic lesions, highlighting the need for new diagnostic tools including disease-specific biomarkers. In this study, Melaseq-FFPE (MEL38) expression in solid tissue biopsies representing the benign nevi to metastatic melanoma spectrum is examined. https://pubmed.ncbi.nlm.nih.gov/34184547/